Ferroptosis Validation in Parkinson's Disease

V2, Crosslink

🧫

Ferroptosis Validation in Parkinson's Disease

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-ferropto

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Ferroptosis Validation in Parkinson's Disease ## Background and Rationale This clinical validation study investigates ferroptosis as a therapeutic target in Parkinson's disease (PD), building on emerging evidence that iron-dependent lipid peroxidation contributes significantly to dopaminergic neurodegeneration. Ferroptosis, a distinct form of regulated cell death characterized by iron accumulation and lipid peroxidation, has been implicated in PD pathogenesis through multiple mechanisms includ

METHODOLOGY NOTES

**Phase 1: In Vitro Model Development (Months 1-12)** • Establish primary dopaminergic neuronal cultures from human iPSCs differentiated using FOXA2/LMX1A protocol • Generate isogenic PD patient-derived iPSC lines with SNCA, LRRK2, and PRKN mutations (n=30 lines per mutation) • Develop ferroptosis induction protocols using erastin (10-20 μM), RSL3 (1-5 μM), and FIN56 (2-10 μM) • Validate ferroptosis markers: lipid peroxidation (C11-BODIPY), iron accumulation (calcein-AM quenching), GPX4 depletion • Screen ferroptosis inhibitors: ferrostatin-1 (1-10 μM), liproxstatin-1 (1-5 μM), vitamin E (50-200 μM) • Measure ATP production, mitochondrial membrane potential, and ROS levels using fluorometric assays **Phase 2: Biomarker Validation (Months 13-24)** • Recruit early-stage PD patients (n=150, Hoehn-Yahr Stage 1-2, UPDRS-III 10-40) • Recruit age-matched healthy controls (n=75) • Collect cerebrospinal fluid via lumbar puncture and plasma samples • Quantify ferroptosis biomarkers: 4-hydroxy

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.906934Z'}
summary	# Ferroptosis Validation in Parkinson's Disease ## Background and Rationale This clinical validation study investigates ferroptosis as a therapeutic target in Parkinson's disease (PD), building on eme
entities	{'genes': ['FERRO'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Demonstration of neuroprotective efficacy of ferroptosis inhibitors in preventing dopaminergic neuron loss in α-synuclein transgenic mouse models and patient-derived cellular systems.
methodology_notes	Phase 1: In Vitro Model Development (Months 1-12) • Establish primary dopaminergic neuronal cultures from human iPSCs differentiated using FOXA2/LMX1A protocol • Generate isogenic PD patient-deri
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.906942', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

739

Outgoing

689

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Ferroptosis Validation in Parkinson's Disease

derives from (16)

supports (31)

💬 Discussion